Replies to post #125928 on Biotech Values

[DewDiligence]

…in the case of multiple entrants, isn't it expected that a company would end up launching an authorized generic? Wouldn't those principles apply to the PFE/FoB Enbrel situation as well?

The manufacturer of a branded drug doesn’t need a partner to make and sell an authorized generic; all they have to do is change the packaging. In the case of Enbrel, if MNTA (or, less likely, some other company) obtained FDA approval for a substitutable Enbrel FoB, AMGN/PFE could launch an AG without any assistance from a third party.